Avuthu Sai Sheela, Mukthinuthalapati Mathrusri Annapurna, Rangisetty Spandana Yasaswini
Avuthu Sai Sheela, Mukthinuthalapati Mathrusri Annapurna*, Rangisetty Spandana Yasaswini
Department of Pharmaceutical Analysis, GITAM Institute of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam-530045, India.
Volume - 13,
Issue - 6,
Year - 2020
Budesonide is a glucocorticoid used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD). Also used to prevent difficulty breathing, chest tightness, wheezing and coughing caused by asthma. A new stability indicating RP-UFLC method has been developed and validated for the determination of Budesonide in pure and pharmaceutical dosage forms. Shimadzu Model CBM-20A/20 Alite UFLC system (Shimadzu Co., Kyoto, Japan) equipped with SPD M20A prominence photodiode array detector on Agilent C18 column was used with a mobile phase consisting of formic acid and ACN (25: 75, v/v) and flow rate 1.2 ml/min (UV detection at 247 nm). Budesonide obeys Beer-Lambert’s law over a concentration range of 10-100 µg/ml. The linear regression equation was found to be y = 35317x + 3515.8 (r2 = 0.9999). The LOD and LOQ was found to be and 2.913 and 8.7643 µg/ml. Budesonide was subjected to forced degradation and the method was validated as per ICH guidelines.
Cite this article:
Avuthu Sai Sheela, Mukthinuthalapati Mathrusri Annapurna, Rangisetty Spandana Yasaswini. New validated stability indicating RP-UFLC method for the determination of Budesonide. Research J. Pharm. and Tech 2020; 13(6): 2819-2824. doi: 10.5958/0974-360X.2020.00502.8
Avuthu Sai Sheela, Mukthinuthalapati Mathrusri Annapurna, Rangisetty Spandana Yasaswini. New validated stability indicating RP-UFLC method for the determination of Budesonide. Research J. Pharm. and Tech 2020; 13(6): 2819-2824. doi: 10.5958/0974-360X.2020.00502.8 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-6-52
1. Christophi GP, Rengarajan A and Ciorba MA. Rectal Budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. Clinical and Experimental Gastroenterology. 2016; 9: 125-130.
2. Stanaland BE. Once-daily Budesonide aqueous nasal spray for allergic rhinitis: A review. Clinical Therapeutics. 2004; 26 (4): 473-492.
3. Silverman J, Otley A. Budesonide in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2011; 7 (4): 419-428.
4. Todd GR, Acerini CL, Buck JJ, Murphy NP, Ross-Russell R, Warner JT, McCance DR. Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate. Eur Respir J. 2002; 19 (6): 1207-1209.
5. O'Donnell S and O'Morain CA: Therapeutic benefits of Budesonide in gastroenterology. Ther Adv Chronic Dis. 2010; 1(4):177-186.
6. Ellul-Micallef R, Hansson E, Johansson SA: Budesonide: a new corticosteroid in bronchial asthma. Eur J Respir Dis. 1980; 61(3):167-173.
7. Shuguang Hou, Michael Hindle, Peter RByron. A stability-indicating HPLC assay method for Budesonide. J Pharm Biomed Anal. 2001; 24(3): 371-380.
8. Sonali RN and Amrita NB. Development of a validated specific HPLC method for Budesonide and characterization of its alkali degradation product. Canadian Journal of Analytical Sciences and Spectroscopy. 2008; 53(3): 113-122.
9. Mukur Gupta and Hridaya NB. Development and validation of a high-performance liquid chromatographic method for the analysis of Budesonide. Journal of Pharmaceutical and Biomedical Analysis. 2006; 40(2): 423-428.
10. Raveendra Babu Gudimitla, Lakshmana Rao Atmakuri , Venkateswara Rao Jangala. A novel method for the estimation of Budesonide in human plasma by using LC-MSMS. Der Pharma Chemica, 2018: 10(4): 181-185.
11. ICH Validation of analytical procedures: Text and methodology Q2 (R1), International Conference on Harmonization (2005).
12. ICH Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization (2003).